Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Heparinase gene covered by U.S., European patents

Sep. 12, 1997

YM-60828: an orally active factor Xa inhibitor from Yamanouchi

Sep. 11, 1997

Reteplase and alteplase exhibit different profiles of fibrin binding at high doses

Sep. 10, 1997

U.S. patent for antithrombotic agents issued to Burnham Institute

Sep. 10, 1997

LG Chemical characterizes new thrombin inhibitor

Sep. 10, 1997

RPR discloses new factor Xa inhibitors

Sep. 10, 1997

Promising phase II results for Genzyme Transgenics' rhATIII

Sep. 9, 1997

Novastan granted priority review status by FDA

Sep. 9, 1997

T-686 inhibits thrombus formation without hemostatic impairment

Sep. 5, 1997

RPR scientists try a new approach to gpIIb/IIIa antagonists

Sep. 5, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...